Jotic, Ana (35173257500)Ana (35173257500)JoticMilovanovic, Jovica (6603250148)Jovica (6603250148)MilovanovicSavic-Vujovic, Katarina (57217857650)Katarina (57217857650)Savic-VujovicRadin, Zorana (57208752128)Zorana (57208752128)RadinMedic, Branislava (56029608400)Branislava (56029608400)MedicFolic, Miljan (56497240500)Miljan (56497240500)FolicPavlovic, Bojan (8212822900)Bojan (8212822900)PavlovicVujovic, Aleksandar (57190496164)Aleksandar (57190496164)VujovicDundjerovic, Dusko (56515503700)Dusko (56515503700)Dundjerovic2025-07-022025-07-022022https://doi.org/10.1177/15593258221115537https://www.scopus.com/inward/record.uri?eid=2-s2.0-85134644134&doi=10.1177%2f15593258221115537&partnerID=40&md5=72a71716bd322d4b6004f3cd62ef2f2ehttps://remedy.med.bg.ac.rs/handle/123456789/12068Objective: The aim of this study was to evaluate cell and biochemical biomarkers and establish their prognostic value in patients with advanced laryngeal cancer. Material and Methods: A prospective study included 52 patients with advanced laryngeal carcinoma surgically treated at the tertiary referral center. Tumor tissue was immunohistochemically stained for T-cell markers (CD4 and CD8), and levels of cytokines (IL-6 and IL-8) and C-reactive protein were analyzed from blood samples. Results: Overall 3-year survival (OS) of patients included in the study was 69.2% and the disease specific survival (DSS) 72.5%. Higher expression of CD4+ and CD8+ were significant prognostic factors with positive impact on both OS and DSS in univariate analysis, but not in multivariate analysis. Levels of IL-8 were a significant predictor of 3-year OS and DSS survival in patients with advanced laryngeal cancer but not levels of IL-6 and CRP values. Conclusion: Though high expression of CD4 and CD8 were demonstrated in the tumor tissue, but their prognostic role was not established. Higher values of IL-8 proved to be significant negative predictor of DSS. This could further collaborate the inclusion of combination of biomarkers in assessment of favorable treatment choice in patients with advanced laryngeal carcinoma. © The Author(s) 2022.advanced laryngeal cancerC-reactive proteincytokinesprognostic biomarkerstumor-infiltrating lymphocytes